This article has Open Peer Review reports available.
Angiolymphoid hyperplasia with eosinophilia: efficacy of isotretinoin?
© El Sayed et al; licensee BioMed Central Ltd. 2006
Received: 28 February 2006
Accepted: 04 October 2006
Published: 04 October 2006
Angiolymphoid hyperplasia with eosinophilia (ALHE) is a benign but potentially disfiguring vascular lesion. It is usually characterized by dermal and subcutaneous nodules, primarily in the head and neck region. Spontaneous regression is common, but persistent or recurrent lesions may require treatment. Several treatments have been reported but surgery is the most efficient one.
Methods and results
We report a 32-year-old man presenting with multiple nodules on the cheeks, preauricular region and the scalp and who received treatment with isotretinoin (0.5 mg/kg/day) for 1 year with complete resolution of one of his scalp nodules. The rest of the lesions remained stable and were treated with surgical excision without recurrence.
Isotretinoin may play a role in the treatment of ALHE due to its antiangiogenic properties via a reduction of vascular endothelial growth factor (VEGF) production by keratinocytes.
Angiolymphoid hyperplasia with eosinophilia (ALHE) is a benign but potentially disfiguring vascular lesion. It is usually characterized by dermal and subcutaneous nodules, primarily in the head and neck region. Spontaneous regression is common, but persistent or recurrent lesions may require treatment . Several treatments have been reported but surgery is the most efficient. We report a new case of ALHE and discuss the efficiency of treatment with isotretinoin.
Methods and results
ALHE was first described in 1969 by Wells and Whimster. It is an uncommon benign vascular tumour which presents with small, dull red papules or nodules, 2–3 cm in diameter usually located on the head and neck, mostly in the vicinity of the ear. Other less common involved sites include the trunk, extremities, genitalia, lips and oral mucosa. ALHE affects young to middle-aged adults with a female predominance. Most lesions are solitary although up to 20% are multiple. They are usually asymptomatic but can be pruritic or painful with compression. Some lesions can be pustatile, ulcerated or can bleed spontaneously. Lymphadenopathy occurs in 5% to 20% of patients. Extracutaneous involvement is rare and has been reported in deep soft tissues, salivary glands, orbit, bone, lymph nodes, colon, heart, lungs and generalized involvement has been described. Blood eosinophilia occurs in 10–20% of cases [2–5].
The etiology of ALHE remains unknown. It is either due to a benign neoplastic proliferation of vascular tissue or a reactive hyperplasia of vascular tissue which develops in response to trauma, infections, renin or hyperestrogenic states (pregnancy or oral contraceptives) [3, 5]. Eosinophils could be actively involved in the pathogenesis of inflammatory reaction by the production of nitric oxide and eosinophilic cationic protein . Although the inflammatory infiltrate in ALHE appears to be an intrinsic component of the disease, it seems fair to assume that ALHE is a benign neoplastic condition. Kempf et al presented evidence that at least a subset of these lesions may represent a T-cell lymphoproliferative disorder of benign or low-grade malignancy [2, 7]. Recently, a malignant transformation has been observed in a young patient with ALHE who developed peripheral T-cell lymphoma .
Histopathologically, ALHE involves the dermis and/or the subcutaneous tissue. It shows anomalous proliferation of dilated small to medium-sized blood vessels with a mixed nodular, perivascular, inflammatory infiltrate composed of lymphocytes, eosinophils, histiocytes, plasma cells, neutrophils and mast cells. The lymphocytes are primarily polytypic B lymphocytes. The affected vessels are tubular, elongated or branching and lined by characteristically plump, hobnail endothelial cells which line and protrude into the lumina of blood vessels, resulting in a characteristic "tombstone" appearance. The endothelial proliferation through the vessel walls produces occlusive vascular changes [1, 5]. Differential diagnoses of ALHE include cutaneous lymphoma, cavernous hemangioma, pyogenic granuloma, Kaposi's sarcoma, angiomatous lymphoid hamartoma, granuloma faciale, polyarteritis nodosa, pseudolymphoma (lymphocytic infiltrate of Jessner, lymphocytoma cutis), persistent insect bite reaction, injection site granuloma and bacillary angiomatosis [2, 5]. In our case, immunohistochemistry rules out other histological differential diagnoses such as epithelioid hemangioendothelioma, B-cell pseudolymphomas, persistent arthropod bite reaction, aluminum-induced granuloma, angiosarcoma and eosinophilic ulcer of the tongue.
Comparison between ALHE and Kimura's disease.
Superficial papules or nodules
Large subcutaneous nodules
Usually one lesion
Head and neck
Head and neck
Third and fourth decades
Regional lymph nodes
Elevated serum IgE
Marked lymphocytic infiltrate and increased mast cell numbers
Exuberant angiomatoid proliferation, masses of uncanalized epithelioid or histiocytoid endothelial cells
Well developed lymphoid follicles
Capillary proliferation with large thick-walled vessels
Origin of the disease
Vascular origin (endothelial cell)
Chronic inflammatory process
Spontaneous remission is common over the course of months to years, but symptomatic and disfiguring lesions may require treatment . Since the patient noted the resolution of one of the scalp nodules with associated decrease in size of the other lesions within the first months of treatment, the possibility of spontaneous remission becomes less likely. Surgical excision is the treatment of choice, but as the lesions are often multilobulated and poorly delineated, local recurrences occur in 33% to 50% after standard surgical excision. Mohs micrographic surgery with complete margin examination can be considered [2, 5]. Surgery can be disfiguring and difficult, especially in the case of periauricular lesions, thus other treatment modalities may be helpful. Treatment options include radiotherapy, curettage, shave excision with electrodessication, cryotherapy, topical, systemic or intralesional corticosteroids, and laser therapy. Continuous-wave carbon dioxide and argon lasers have been successful for treating ALHE but there is a risk of post-treatment scarring. The pulsed dye laser minimizes this risk. Anecdotal reports describe success with intralesional interferon α-2a, indomethacin farnestil, pentoxyfylline, chemotherapeutic agents such as vinblastine, mepolizumab (anti-IL-5) and imiquimod [1–3, 9, 10].
Treatment of ALHE with oral retinoids has been mentioned in the medical literature with different results. Marcoux et al reported a 62-year old female with multiple asymptomatic scalp nodules diagnosed as having ALHE, who was treated with acitretin (1 mg/kg/day) and had complete resolution of her scalp nodules after 4 months of treatment . Oh et al reported a 48-year old female with scalp and postauricular nodules who was treated surgically with recurrence of her lesions after 2 months of excision. Thus, a trial of treatment with isotretinoin (30 mg/day) was done with a decrease in size and number of the lesions after 2 months. However, the lesions recurred upon withdrawal of isotretinoin . In our case, isotretinoin was able to stabilize the disease, to eradicate one scalp nodule and to decrease the size of the remaining nodules. This effect may be due to the capacity of retinoids to inhibit angiogenesis via the reduction of vascular endothelial growth factor (VEGF) production by keratinocytes. The anti-activator protein 1 (AP1) activity of the retinoid molecules is responsible for the inhibition of the VEGF expression. In fact, VEGF genes' expression is down-regulated by retinoids via the inhibition of the AP1 pathway .
- Angel C, Lewis A, Griffin T, Levy E, Benedetto A: Angiolymphoid hyperplasia successfully treated with an ultralong pulsed dye laser. Dermatol Surg. 2005, 31: 713-16.View ArticlePubMedGoogle Scholar
- Shankar S, Russell-Jones R: Co-existence of lichen amyloidosis and angiolymphoid hyperplasia with eosinophilia. Clin Exp Dermatol. 2004, 29: 363-365. 10.1111/j.1365-2230.2004.01517.x.View ArticlePubMedGoogle Scholar
- Kaur T, Sandhu K, Gupta S, Kanwar AJ, Kumar B: Treatment of angiolymphoid hyperplasia with eosinophilia with the carbon dioxide laser. J Dermatolog Treat. 2004, 15 (5): 328-330. 10.1080/09546630410015547.View ArticlePubMedGoogle Scholar
- Moran CA, Suster S: Angiolymphoid hyperplasia with eosinophilia (epithelioid hemangioma) of the lung: a clinicopathologic and immunohistochemical study of two cases. Am J Clin Pathol. 2005, 123: 762-765. 10.1309/UN1A-Q2WJ-U9HD-D72F.View ArticlePubMedGoogle Scholar
- Miller CJ, Ioffreda MD, Ammirati CT: Mohs micrographic surgery for angiolymphoid hyperplasia with eosinophilia. Dermatol Surg. 2004, 30: 1169-1173. 10.1111/j.1524-4725.2004.30349.x.PubMedGoogle Scholar
- Andreae J, Galle C, Magdorf K, Staab D, Meyer L, Goldman M, Querfeld U: Severe atherosclerosis of the aorta and development of peripheral T-cell lymphoma in an adolescent with angiolymphoid hyperplasia with eosinophilia. Br J Dermatol. 2005, 152: 1033-1038. 10.1111/j.1365-2133.2005.06421.x.View ArticlePubMedGoogle Scholar
- Kempf W, Haeffner AC, Zepter K, Sander CA, Flaig MJ, Mueller B, Panizzon RG, Hardmeier T, Adams V, Burg G: Angiolymphoid hyperplasia with eosinophilia: evidence for a T-cell lymphoproliferative origin. Hum Pathol. 2002, 33: 1023-1029. 10.1053/hupa.2002.128247.View ArticlePubMedGoogle Scholar
- Satpathy A, Moss C, Raafat F, Slator R: Spontaneous regression of a rare tumour in a child: angiolymphoid hyperplasia with eosinophilia of the hand: case report and review of the literature. Br J Plast Surg. 2005, 58: 865-868. 10.1016/j.bjps.2004.11.014.View ArticlePubMedGoogle Scholar
- Braun-Falco M, Fischer S, Prötz SG, Ring J: Angiolymphoid hyperplasia with eosinophilia treated with anti-interleukin-5 antibody (mepolizumab). Br J Dermatol. 2004, 151: 1103-1104. 10.1111/j.1365-2133.2004.06239.x.View ArticlePubMedGoogle Scholar
- Redondo P, Del Olmo J, Idoate M: Angiolymphoid hyperplasia with eosinophilia successfully treated with imiquimod. Br J Dermatol. 2004, 151: 1110-1111. 10.1111/j.1365-2133.2004.06263.x.View ArticlePubMedGoogle Scholar
- Marcoux C, Bourlond A, Decroix J: Hyperplasie angio-lymphoïde avec éosinophilie: rémission sous acitrétine. Ann Dermatol Venereol. 1991, 118: 217-221.PubMedGoogle Scholar
- Oh CW, Kim KH: Is angiolymphoid hyperplasia with eosinophilia a benign vascular tumor? A case improved with oral isotretinoin. Dermatology. 1998, 197: 189-191.PubMedGoogle Scholar
- Diaz BV, Lenoir MC, Ladoux A, Frelin C, Demarchez M, Michel S: Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids. J Biol Chem. 2000, 275: 642-650. 10.1074/jbc.275.1.642.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.